Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis
暂无分享,去创建一个
[1] G. Remuzzi,et al. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome , 2023, International journal of molecular sciences.
[2] M. Saleem,et al. What is circulating factor disease and how is it currently explained? , 2023, Pediatric Nephrology.
[3] D. Altshuler,et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. , 2023, The New England journal of medicine.
[4] C. Thongprayoon,et al. Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review , 2023, Renal failure.
[5] C. Srichomthong,et al. Pathogenic variant detection rate by whole exome sequencing in Thai patients with biopsy-proven focal segmental glomerulosclerosis , 2023, Scientific Reports.
[6] L. M. dos Reis,et al. Urinary CD80 and Serum suPAR as Biomarkers of Glomerular Disease among Adults in Brazil , 2023, Diagnostics.
[7] S. Sanjad,et al. Current Understanding of Nephrotic Syndrome in Children. , 2022, Pediatric clinics of North America.
[8] P. Heeger,et al. Cutting Edge: Neutrophil Complement Receptor Signaling Is Required for BAFF-Dependent Humoral Responses in Mice. , 2022, Journal of immunology.
[9] G. Tobón,et al. B-cell activating factor (BAFF) and its receptors’ expression in pediatric nephrotic syndrome is associated with worse prognosis , 2022, PloS one.
[10] G. La Manna,et al. Decay-Accelerating Factor Expression Modulates the Severity of Experimental Focal Segmental Glomerulosclerosis , 2022, Kidney360.
[11] A. Sidhom. ATYPICAL IPEX SYNDROME PRESENTING AS SEVERE APLASTIC ANEMIA AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS RESPONSIVE TO TACROLIMUS , 2022, Annals of Allergy, Asthma & Immunology.
[12] J. Lieske,et al. Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. , 2022, Kidney international.
[13] M. Indeykina,et al. Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease , 2022, International journal of molecular sciences.
[14] J. Deegens,et al. Novel mouse strains to study circulating permeability factor(s) in primary focal segmental glomerulosclerosis , 2022, PLoS ONE.
[15] A. Liew,et al. How I Treat Focal Segmental Glomerulosclerosis , 2022, Clinical journal of the American Society of Nephrology : CJASN.
[16] M. Sambharia,et al. Monogenic focal segmental glomerulosclerosis: A conceptual framework for identification and management of a heterogeneous disease , 2022, American journal of medical genetics. Part C, Seminars in medical genetics.
[17] Wen-Jing Zhao,et al. Transition from minimal change disease to focal segmental glomerulosclerosis related to occupational exposure: A case report , 2022, World journal of clinical cases.
[18] H. Alhozali,et al. Histopathological and Clinical Findings of Biopsy-Proven Focal and Segmental Glomerulosclerosis: A Retrospective Study , 2022, Cureus.
[19] A. Sinha,et al. Interventions for focal segmental glomerulosclerosis in adults. , 2022, The Cochrane database of systematic reviews.
[20] K. Huang,et al. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma , 2022, Frontiers in Immunology.
[21] A. Bonnefoy,et al. Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis , 2022, Kidney international reports.
[22] M. Vivarelli,et al. B-Cell Dysregulation in Idiopathic Nephrotic Syndrome: What We Know and What We Need to Discover , 2022, Frontiers in Immunology.
[23] I. Shaheen,et al. Management of recurrent focal segmental glomerulosclerosis (FSGS) post renal transplantation. , 2021, Transplantation reviews.
[24] K. Campbell,et al. Urine single cell RNA-sequencing in FSGS – hope for the future. , 2021, Kidney International Reports.
[25] N. Chebotareva,et al. Serum levels of plasminogen activator urokinase receptor and cardiotrophin-like cytokine factor 1 in patients with nephrotic syndrome. , 2021, Clinical nephrology.
[26] S. Waikar,et al. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology , 2021, Journal of the American Society of Nephrology : JASN.
[27] J. Wetzels,et al. Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling , 2021, bioRxiv.
[28] B. Rovin,et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.
[29] B. Rovin,et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.
[30] Jianhua Mao,et al. Seven novel podocyte autoantibodies were identified to diagnosis a new disease subgroup-autoimmune Podocytopathies. , 2021, Clinical immunology.
[31] G. Ghiggeri,et al. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome , 2021, Frontiers in Immunology.
[32] M. Prunotto,et al. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial , 2021, Journal of the American Society of Nephrology : JASN.
[33] B. Rovin,et al. Natural Antibody and Complement Activation Characterize Patients with Idiopathic Nephrotic Syndrome. , 2021, American journal of physiology. Renal physiology.
[34] F. Emma,et al. Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study , 2021, Pediatric Nephrology.
[35] N. Iwasaki,et al. Cardiotrophin like cytokine factor 1 (CLCF1) alleviates bone loss in osteoporosis mouse models by suppressing osteoclast differentiation through activating interferon signaling and repressing the nuclear factor-κB signaling pathway. , 2021, Bone.
[36] A. Moktefi,et al. CMIP interacts with WT1 and targets it on the proteasome degradation pathway , 2021, Clinical and translational medicine.
[37] A. Pukajło-Marczyk,et al. Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome , 2021, Journal of clinical medicine.
[38] A. Bouts,et al. Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis , 2021, Pediatrics.
[39] M. Hogan,et al. Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. , 2021, Mayo Clinic proceedings.
[40] J. Wetzels,et al. Therapeutic trials in adult FSGS: lessons learned and the road forward , 2021, Nature Reviews Nephrology.
[41] B. Knebelman,et al. Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys , 2021, Kidney international reports.
[42] N. Carlozzi,et al. Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes , 2021, Kidney medicine.
[43] Y. Chan,et al. Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. , 2021, Translational research : the journal of laboratory and clinical medicine.
[44] Jingwen Huang,et al. Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women , 2021, BMC Musculoskeletal Disorders.
[45] Qiang Sun,et al. Decreased Circulating Transitional B-Cell to Memory B-Cell Ratio Is a Risk Factor for Relapse in Children with Steroid-Sensitive Nephrotic Syndrome , 2020, Nephron.
[46] R. Nee,et al. Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression. , 2020, Kidney360.
[47] E. Audureau,et al. Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] S. Kalkhof,et al. Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis , 2020, Scientific Reports.
[49] C. Ponticelli,et al. Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association , 2020, Frontiers in Medicine.
[50] L. Gesualdo,et al. High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[51] T. Meitinger,et al. Identification of disease-causing variants by comprehensive genetic testing with exome sequencing in adults with suspicion of hereditary FSGS , 2020, European Journal of Human Genetics.
[52] G. Remuzzi,et al. Podocytopathies , 2020, Nature Reviews Disease Primers.
[53] A. Levin,et al. Alport Syndrome Classification and Management , 2020, Kidney medicine.
[54] G. Fernández-Juárez,et al. Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective , 2020, Nephron.
[55] H. Trimarchi. Focal Segmental Glomerulosclerosis and Scheduled Pretransplant Plasmapheresis: A Timely Diagnosis of Nail-Patella Syndrome Avoided More Futile Immunosuppression , 2020, Case reports in nephrology.
[56] D. Friedman,et al. APOL1 Nephropathy: From Genetics to Clinical Applications. , 2020, Clinical journal of the American Society of Nephrology : CJASN.
[57] Shigeru Tanaka,et al. Utility of Columbia classification in focal segmental glomerulosclerosis: renal prognosis and treatment response among the pathological variants. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[58] Ming-hui Zhao,et al. Complement activation profile of patients with primary focal segmental glomerulosclerosis , 2020, PloS one.
[59] A. Bomback,et al. Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[60] C. Thongprayoon,et al. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis , 2020, BMC Nephrology.
[61] B. Kasiske,et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. , 2020, Transplantation.
[62] G. M. Neto,et al. Recurrence of FSGS after Kidney Transplantation in Adults. , 2020, Clinical journal of the American Society of Nephrology : CJASN.
[63] K. Nakanishi,et al. Comprehensive genetic diagnosis of Japanese patients with severe proteinuria , 2020, Scientific Reports.
[64] H. Lorenzo,et al. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle , 2019, Cell and Tissue Research.
[65] M. Saleem. Molecular stratification of idiopathic nephrotic syndrome , 2019, Nature Reviews Nephrology.
[66] Qiang Sun,et al. Altered B-Lymphocyte Homeostasis in Idiopathic Nephrotic Syndrome , 2019, Front. Pediatr..
[67] V. Nair,et al. Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis , 2019, PloS one.
[68] M. Rastaldi,et al. Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome. , 2019, Kidney international.
[69] M. Saleem,et al. Human Th17 cells produce a soluble mediator that increases podocyte motility via signalling pathways which mimic PAR-1 activation. , 2019, American journal of physiology. Renal physiology.
[70] D. Geary,et al. Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics , 2019, Kidney international reports.
[71] Wasim Hussain,et al. Follicular B2 Cell Activation and Class Switch Recombination Depend on Autocrine C3ar1/C5ar1 Signaling in B2 Cells , 2019, The Journal of Immunology.
[72] R. B. Henderson,et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[73] Thomas M. Kitzler,et al. Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis , 2019, PloS one.
[74] E. Rocha-Vieira,et al. Pediatric Patients With Steroid-Sensitive Nephrotic Syndrome Have Higher Expression of T Regulatory Lymphocytes in Comparison to Steroid-Resistant Disease , 2019, Front. Pediatr..
[75] S. Rieder,et al. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. , 2019, Advanced drug delivery reviews.
[76] A. Paterson,et al. Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[77] J. Reiser,et al. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab , 2018, BMC Nephrology.
[78] A. Bagga,et al. Management of steroid-resistant nephrotic syndrome in children and adolescents. , 2018, The Lancet. Child & adolescent health.
[79] O. Gribouval,et al. Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults. , 2018, Kidney international.
[80] G. Gambaro,et al. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. , 2018, Journal of the American Society of Nephrology : JASN.
[81] F. Emma,et al. B cell phenotype in pediatric idiopathic nephrotic syndrome , 2018, Pediatric Nephrology.
[82] M. Rudnicki,et al. Successful management of recurrent focal segmental glomerulosclerosis , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[83] R. Parekh,et al. Idiopathic nephrotic syndrome in children , 2018, The Lancet.
[84] R. B. Henderson,et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial , 2018, The Lancet.
[85] E. Daugas,et al. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. , 2018, Journal of autoimmunity.
[86] S. Funk,et al. Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane. , 2018, Matrix biology : journal of the International Society for Matrix Biology.
[87] C. Alpers,et al. AJKD Atlas of Renal Pathology: Pierson Syndrome. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[88] K. Nath,et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. , 2018, Journal of the American Society of Nephrology : JASN.
[89] G. Fernández-Juárez,et al. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults , 2018, Clinical kidney journal.
[90] P. O'kelly,et al. Renal transplant outcomes in primary FSGS compared with other recipients and risk factors for recurrence: A national review of the Irish Transplant Registry , 2018, Clinical transplantation.
[91] R. Lennon,et al. Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? , 2017, Pediatric Nephrology.
[92] G. Camussi,et al. Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS , 2017, PloS one.
[93] M. Saleem,et al. Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances , 2017, Pediatric Nephrology.
[94] D. Youssef,et al. Tumor necrosis factor alpha gene polymorphisms and haplotypes in Egyptian children with nephrotic syndrome , 2017, Cytokine.
[95] Chris Buxton,et al. Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations , 2017, Journal of Medical Genetics.
[96] S. Beaudreuil,et al. Optimal management of primary focal segmental glomerulosclerosis in adults , 2017, International journal of nephrology and renovascular disease.
[97] Joseph H. Marcus,et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk , 2017, The New England journal of medicine.
[98] M. Lanaspa,et al. Angiopoietin-like-4 and minimal change disease , 2017, PloS one.
[99] W. Dixon,et al. Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community , 2017, BMJ Open.
[100] J. Yazdany,et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. , 2017, Autoimmunity reviews.
[101] F. Emma,et al. Minimal Change Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[102] F. Cosio,et al. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. , 2017, Kidney international.
[103] M. Stangou,et al. Impact of Τh1 and Τh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease , 2016, Journal of nephropathology.
[104] D. Scadden,et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease , 2016, Nature Medicine.
[105] B. Smeets,et al. Minimal change disease and idiopathic FSGS: manifestations of the same disease , 2016, Nature Reviews Nephrology.
[106] A. Więcek,et al. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. , 2016, Transplantation proceedings.
[107] Ming-hui Zhao,et al. Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[108] M. Saleem,et al. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View , 2016, Journal of immunology research.
[109] Richard J. Johnson,et al. Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms , 2016, Pediatric Nephrology.
[110] G. Remuzzi,et al. A previously unrecognized role of C3a in proteinuric progressive nephropathy , 2016, Scientific Reports.
[111] L. Ravà,et al. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. , 2016, Journal of the American Society of Nephrology : JASN.
[112] L. Laurin,et al. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[113] I. Barlan,et al. The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome , 2016, European Journal of Pediatrics.
[114] Geetha Chalasani,et al. B Cells, Antibodies, and More. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[115] T. Slowinski,et al. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor–Mediated Podocyte &bgr;3-integrin Activation , 2015, Transplantation.
[116] G. Vlachopanos,et al. Plasma Exchange for the Recurrence of Primary Focal Segmental Glomerulosclerosis in Adult Renal Transplant Recipients: A Meta-Analysis , 2015, Journal of transplantation.
[117] T. Srivastava,et al. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. , 2015, Translational research : the journal of laboratory and clinical medicine.
[118] D. Gipson,et al. Complement Activation in Patients with Focal Segmental Glomerulosclerosis , 2015, PloS one.
[119] T. Srivastava,et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group , 2015, BMC Nephrology.
[120] T. Srivastava,et al. Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family , 2015, Journal of immunology research.
[121] J. Davin. The glomerular permeability factors in idiopathic nephrotic syndrome , 2015, Pediatric Nephrology.
[122] A. Anarat,et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[123] H. Cheong,et al. Familial IPEX syndrome: Different glomerulopathy in two siblings , 2015, Pediatrics international : official journal of the Japan Pediatric Society.
[124] A. C. Simões e Silva,et al. The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update , 2015, Inflammation Research.
[125] A. Fogo. Causes and pathogenesis of focal segmental glomerulosclerosis , 2015, Nature Reviews Nephrology.
[126] J. Deegens,et al. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[127] V. Jha,et al. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[128] M. Sarwal,et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation , 2014, Science Translational Medicine.
[129] M. Kretzler,et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease , 2014, Kidney international.
[130] V. D’Agati,et al. Morphologic variants of focal segmental glomerulosclerosis and their significance. , 2014, Advances in chronic kidney disease.
[131] J. Radhakrishnan,et al. The treatment of idiopathic focal segmental glomerulosclerosis in adults. , 2014, Advances in chronic kidney disease.
[132] I. Pastan,et al. Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[133] M. Rudnicki,et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.
[134] D. Cattran,et al. Glomerular diseases: FSGS. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[135] R. Pandey,et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. , 2014, Kidney international.
[136] M. Nangaku,et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. , 2014, Kidney international.
[137] J. Deegens,et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. , 2014, Kidney international.
[138] S. Kersten,et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome , 2013, Nature Medicine.
[139] H. Trachtman,et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[140] C. Langman,et al. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[141] A. Moudgil,et al. Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome , 2013, Pediatric Nephrology.
[142] J. Deegens,et al. Serum suPAR in patients with FSGS: trash or treasure? , 2013, Pediatric Nephrology.
[143] V. D’Agati,et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[144] J. Thurman,et al. IgM contributes to glomerular injury in FSGS. , 2013, Journal of the American Society of Nephrology : JASN.
[145] G. Remuzzi,et al. Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[146] J. Pers,et al. The complexity of the BAFF TNF-family members: implications for autoimmunity. , 2012, Journal of autoimmunity.
[147] Richard J. H. Smith,et al. Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[148] J. Pers,et al. B-lymphocytes govern the pathogenesis of Sjögren's syndrome. , 2012, Current pharmaceutical biotechnology.
[149] A. Fornoni,et al. Podocyte Foot Process Effacement in Postreperfusion Allograft Biopsies Correlates With Early Recurrence of Proteinuria in Focal Segmental Glomerulosclerosis , 2012, Transplantation.
[150] L. Rostaing,et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[151] J. Leventhal,et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. , 2012, The New England journal of medicine.
[152] S. Chugh,et al. New insights into human minimal change disease: lessons from animal models. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[153] V. D’Agati,et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. , 2011, Kidney international.
[154] E. Salido,et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.
[155] M. Kopač,et al. Partial Remission of Resistant Nephrotic Syndrome After Oral Galactose Therapy , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[156] M. Rastaldi,et al. Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.
[157] Xia Li,et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. , 2011, Clinical immunology.
[158] B. Tazón-Vega,et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[159] T. Greene,et al. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. , 2011, Kidney international.
[160] K. Pfeiffer,et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. , 2011, Journal of the American Society of Nephrology : JASN.
[161] D. Harris,et al. Adriamycin nephropathy: A model of focal segmental glomerulosclerosis , 2011, Nephrology.
[162] V. Savin,et al. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[163] S. Kersten,et al. Podocyte secreted Angiopoietin-like 4 mediates proteinuria in glucocorticoid sensitive nephrotic syndrome , 2010, Nature Medicine.
[164] Juan I. Young,et al. Podocyte-Specific Overexpression of Wild Type or Mutant Trpc6 in Mice Is Sufficient to Cause Glomerular Disease , 2010, PloS one.
[165] K. Dahan,et al. c-mip Impairs Podocyte Proximal Signaling and Induces Heavy Proteinuria , 2010, Science Signaling.
[166] R. Salomon,et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[167] Jesper Eugen-Olsen,et al. suPAR: The Molecular Crystal Ball , 2009, Disease markers.
[168] M. Dallman,et al. Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. , 2009, Journal of the American Society of Nephrology : JASN.
[169] C. Déziel,et al. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[170] N. Printza,et al. Peripheral CD19+ B cells are increased in children with active steroid-sensitive nephrotic syndrome , 2009, NDT plus.
[171] M. Atkinson,et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome , 2009, Pediatric Nephrology.
[172] S. Hillion,et al. Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. , 2009, Arthritis and rheumatism.
[173] M. Cancro,et al. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. , 2009, The Journal of clinical investigation.
[174] C. Alpers,et al. Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. , 2009, The Journal of clinical investigation.
[175] S. Leroy,et al. Successful Anti‐TNFα Treatment in a Child with Posttransplant Recurrent Focal Segmental Glomerulosclerosis , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[176] S. Shankland,et al. Inducible rodent models of acquired podocyte diseases. , 2009, American journal of physiology. Renal physiology.
[177] S. Satchell,et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. , 2008, Journal of the American Society of Nephrology : JASN.
[178] Maristela L Onozato,et al. Glomerular albumin filtration through podocyte cell body in puromycin aminonucleoside nephrotic rat , 2008, Medical Molecular Morphology.
[179] V. Savin,et al. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. , 2008, Translational research : the journal of laboratory and clinical medicine.
[180] V. Jha,et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[181] C. Antignac,et al. A missense mutation in podocin leads to early and severe renal disease in mice. , 2008, Kidney international.
[182] V. D’Agati. The spectrum of focal segmental glomerulosclerosis: new insights , 2008, Current opinion in nephrology and hypertension.
[183] H. Kawachi,et al. Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. , 2008, Kidney international.
[184] E. Haddad,et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. , 2007, Journal of the American Society of Nephrology : JASN.
[185] P. Tan,et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. , 2007, Journal of the American Society of Nephrology : JASN.
[186] F. Hildebrandt,et al. Nephrotic Syndrome in the First Year of Life: Two Thirds of Cases Are Caused by Mutations in 4 Genes (NPHS1, NPHS2, WT1, and LAMB2) , 2007, Pediatrics.
[187] S. Shankland,et al. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. , 2006, Kidney international.
[188] V. D’Agati,et al. Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. , 2006, Kidney international.
[189] P. Schneider,et al. BAFF, APRIL and their receptors: structure, function and signaling. , 2006, Seminars in immunology.
[190] L. Gesualdo,et al. Posttransplant Recurrence of Proteinuria in a Case of Focal Segmental Glomerulosclerosis Associated with WT1 Mutation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[191] A. E. El Nahas,et al. Immunosuppressive Treatment of Idiopathic Focal Segmental Glomerulosclerosis: A Five-Year Follow-Up Study , 2006, Nephron Clinical Practice.
[192] R J Falk,et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. , 2006, Kidney international.
[193] B. Sampaio-Maia,et al. Blunted renal dopaminergic system activity in puromycin aminonucleoside-induced nephrotic syndrome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[194] C. Usal,et al. Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats. , 2005, Kidney international.
[195] L. Holzman,et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. , 2005, Journal of the American Society of Nephrology : JASN.
[196] B. Tönshoff,et al. Recurrence of Focal-Segmental Glomerulosclerosis in Children after Renal Transplantation: Clinical and Genetic Aspects , 2005, Transplantation.
[197] J. Scholey,et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. , 2005, Journal of the American Society of Nephrology : JASN.
[198] I. Pastan,et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. , 2005, Journal of the American Society of Nephrology : JASN.
[199] D. Adu,et al. Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. , 2005, Kidney international.
[200] N. Duncan,et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[201] G. Appel,et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. , 2004, Clinical nephrology.
[202] W. Couser,et al. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. , 2004, Kidney international.
[203] G. Vlotides,et al. Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC)--a novel gp130 cytokine with pleiotropic functions. , 2004, Cytokine & growth factor reviews.
[204] D. Raveh,et al. Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome , 2004, Pediatric Nephrology.
[205] Agnes B Fogo,et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[206] B. Smeets,et al. Podocyte changes upon induction of albuminuria in Thy-1.1 transgenic mice. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[207] K. Anderson,et al. Functional significance of novel neurotrophin‐1/B cell‐stimulating factor‐3 (cardiotrophin‐like cytokine) for human myeloma cell growth and survival , 2003, British journal of haematology.
[208] Y. Tay,et al. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. , 2003, Kidney international.
[209] R. Oppenheim,et al. Cardiotrophin-Like Cytokine/Cytokine-Like Factor 1 is an Essential Trophic Factor for Lumbar and Facial Motoneurons In Vivo , 2003, The Journal of Neuroscience.
[210] R. Gerszten,et al. Mice deficient in α-actinin-4 have severe glomerular disease , 2003 .
[211] A. Berg,et al. Production of hemopexin by TNF-α stimulated human mesangial cells , 2003 .
[212] B. Vanderhyden,et al. Focal and Segmental Glomerulosclerosis in Mice with Podocyte-Specific Expression of Mutant α-Actinin-4 , 2003 .
[213] V. D’Agati,et al. Pathologic classification of focal segmental glomerulosclerosis. , 2003, Seminars in nephrology.
[214] M. Pollak. The genetic basis of FSGS and steroid-resistant nephrosis. , 2003, Seminars in nephrology.
[215] P. Eggers,et al. Trends in the epidemiology of focal segmental glomerulosclerosis. , 2003, Seminars in nephrology.
[216] B. Nardelli,et al. G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS , 2003, The Journal of experimental medicine.
[217] J. Wetzels,et al. Antibody-induced albuminuria and accelerated focal glomerulosclerosis in the Thy-1.1 transgenic mouse. , 2002, Kidney international.
[218] W. Wurst,et al. Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions. , 2002, Journal of the American Society of Nephrology : JASN.
[219] R. Faggioni,et al. Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function , 2002, The Journal of Immunology.
[220] R. Cunard,et al. T cells and minimal change disease. , 2002, Journal of the American Society of Nephrology : JASN.
[221] F. Altruda,et al. Hemopexin: structure, function, and regulation. , 2002, DNA and cell biology.
[222] D. Kerjaschki,et al. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. , 2002, The Journal of clinical investigation.
[223] D. Kerjaschki,et al. The Buffalo/Mna rat, an animal model of FSGS recurrence after renal transplantation. , 2001, Transplantation proceedings.
[224] Y. H. Kim,et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. , 2001, Kidney international.
[225] T. Graf,et al. Anuria, Omphalocele, and Perinatal Lethality in Mice Lacking the Cd34-Related Protein Podocalyxin , 2001, The Journal of experimental medicine.
[226] Y. Wang,et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. , 2000, Kidney international.
[227] M. Herrmann,et al. Dominant T cells in idiopathic nephrotic syndrome of childhood. , 2000, Kidney international.
[228] J. Baller,et al. Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. , 2000, Kidney international.
[229] L. Hebert,et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. , 1999, Kidney international.
[230] Michael Loran Dustin,et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. , 1999, Science.
[231] T. Boone,et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[232] S. Ruben,et al. Computational EST database analysis identifies a novel member of the neuropoietic cytokine family. , 1999, Biochemical and biophysical research communications.
[233] S. Adler,et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[234] D. Cattran,et al. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[235] G. Nyberg,et al. Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms , 1998, Transplant international : official journal of the European Society for Organ Transplantation.
[236] S. Swan,et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. , 1996, The New England journal of medicine.
[237] K. Furusho,et al. Involvement of interleukin (IL)‐13, but not IL‐4, in spontaneous IgE and IgG4 production in nephrotic syndrome , 1995, European journal of immunology.
[238] M. Schwartz,et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[239] E. Lewis,et al. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[240] V. Savin,et al. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[241] A. Edefonti,et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome , 1993, Pediatric Nephrology.
[242] A. Koyama,et al. A glomerular permeability factor produced by human T cell hybridomas. , 1991, Kidney international.
[243] C. Ponticelli,et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. , 1991, Clinical nephrology.
[244] B. Brenner,et al. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. , 1988, The Journal of clinical investigation.
[245] E. Girardin,et al. Immunopathological findings in idiopathic nephrosis: Clinical significance of glomerular “immune deposits” , 1988, Pediatric Nephrology.
[246] G. Kollias,et al. Ectopic expression of Thy-1 in the kidneys of transgenic mice induces functional and proliferative abnormalities , 1987, Cell.
[247] M. Karnovsky,et al. Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. , 1986, The American journal of pathology.
[248] M. Fujishima,et al. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. , 1986, Kidney international.
[249] R. Shalhoub. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. , 1974, Lancet.
[250] A. Michael,et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. , 1972, Lancet.
[251] B. Ansell. Corticosteroids , 2019, Reactions Weekly.
[252] W. Tangheroni,et al. [Proteinuria caused by transfusion of blood from nephrotic to non-nephrotic individuals]. , 1954, Minerva medica.
[253] OUP accepted manuscript , 2022, Clinical Kidney Journal.
[254] A. Jamin,et al. Idiopathic nephrotic syndrome: the EBV hypothesis , 2017, Pediatric Research.
[255] J. Kopp,et al. Focal Segmental Glomerulosclerosis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[256] R. Kew. The Complement System , 2014 .
[257] V. D’Agati,et al. Focal segmental glomerulosclerosis. , 2011, The New England journal of medicine.
[258] D. Gipson,et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[259] P. Carmeliet,et al. Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.
[260] L. Sklar,et al. Chemotactic Peptide/Complement Receptors , 2004 .
[261] K. Tryggvason,et al. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. , 2001, Human molecular genetics.
[262] A. Meyrier. Treatment of primary focal segmental glomerulosclerosis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[263] S. Korbet. Clinical picture and outcome of primary focal segmental glomerulosclerosis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[264] S. Zimmerman. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. , 1984, Clinical nephrology.
[265] G. Remuzzi,et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. , 1982, Laboratory investigation; a journal of technical methods and pathology.
[266] The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. , 1981, The Journal of pediatrics.